MHRA - Importing investigational medicinal products into Great Britain from approved countries from 1 January 2021

21st October 2020

Sponsors of UK clinical trials that import investigational medicinal products (IMPs) into Great Britain from outside the UK will need to review their existing supply chains.

Where the product is sourced from a country on the ‘approved country for import list’, this will include a UK Manufacturing and Import Authorisation (MIA(IMP)) holder putting in place an assurance system to check these IMPs have been certified by a Qualified Person (QP) in a listed country, before release to trial sites. The list of approved countries will initially include all EU and EEA countries.

IMPs imported into Great Britain from outside the UK that have been QP certified in a listed country will not require recertification in Great Britain.

The purpose of this guidance is to describe the principles for the management and oversight of the import of IMPs to Great Britain from listed countries. There will be a one-year transition period from 1 January 2021.

More Information

Back to News Archive